Related Experiment Video
Updated: Jul 18, 2025
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.2K
C3G and Ig-MPGN-treatment standard
Marina Noris1, Giuseppe Remuzzi1
1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Daccò Ranica, Bergamo, Italy.
Summary
Membranoproliferative glomerulonephritis (MPGN) includes C3 glomerulopathy (C3G) and immunoglobulin-associated MPGN (Ig-MPGN). Unsupervised clustering identified four distinct pathogenic clusters, paving the way for targeted therapies.
Area of Science:
- Nephrology
- Immunology
- Complement System Biology
Background:
- Membranoproliferative glomerulonephritis (MPGN) is classified by immunofluorescence into C3 glomerulopathy (C3G) with dominant C3 deposits and immunoglobulin-associated MPGN (Ig-MPGN) with C3 and immunoglobulin deposits.
- C3G and Ig-MPGN share overlapping features, including low serum C3 levels, complement alternative pathway abnormalities, and potential for pattern shifts between biopsies.
- Both conditions have an unfavorable prognosis with limited specific therapies, relying mainly on renoprotective agents, with variable responses to existing treatments like corticosteroids and eculizumab.
Conclusions:
- Accurate diagnosis and understanding of heterogeneous pathogenesis are crucial for C3G and Ig-MPGN management.
- Targeted therapies based on identified pathogenic clusters hold promise for improving patient outcomes.
- Further research and clinical trials are essential to optimize treatment strategies for these complex glomerular diseases.
